AACR 2023 posters

AACR 2023 posters

We’re attending AACR 2023, held from April 14-19 in Orlando, Florida! For the latest advances, service offerings, and promotions, register now to visit our team at Booth 723, which will be open from April 16-19. Be sure to also visit our 25 posters, which can now be added to your AACR itinerary.

Off-the-Shelf Mouse Model Posters

Target Mouse model Poster
CCR8 B-hPD-1/hPD-L1/hCCR8 mice A Novel Triple Humanized B-hPD-1/hPD-L1/hCCR8 Mouse Model to Evaluate In vivo Efficacy of Combination Therapies
CD94/NKG2A B-hCD94/hNKG2A mice B-hCD94/hNKG2A Mice Provide a Preclinical Tool for Evaluating Therapeutic Antibodies Targeting Human NKG2A
MGMT3 B-NDG MGMT3 mice Development of Immunodeficient Mice Expressing Human IL3, GM-CSF, CSF1 and THPO for Improved Human Myeloid and Lymphoid Cell Reconstitution
MHC DKO B-NDG MHC I/II DKO mice plus Development of MHC I/II Knock-Out Immunodeficient Mouse Strains for Alleviating GvHD Induced by Human PBMC Reconstitution
TREM2 B-hTREM2 mice Generation of Humanized TREM2 Mice for Preclinical Evaluation of Therapeutics Targeting Tumor-Associated Macrophages
hOX40/Ox40L  B-hOX40/hOX40L mice Humanized OX40/OX40L Mice as a Tool for Evaluating Novel Therapeutics
hVEGFR2 B-hVEGFR2 mice In vivo Efficacy Evaluation of Anti-Human VEGFR2 Antibodies in Humanized B-hVEGFR2 Mice
hIL11RA B-hIL11RA mice In vivo Efficacy of an Anti-Human IL11RA Antibody in B-hIL11RA Mice With APAP-Induced Liver Damage
CD36 B-hCD36 mice Novel Humanized CD36 Mouse Model for Therapeutic Studies

RenMabTM-Based Fully Human Antibody Discovery Platforms

Platform Poster
RenNano® TFR1 Discovery of RenNano®-Derived Human Heavy-Chain-Only Antibodies That Cross the Blood-Brain-Barrier
RenNano® RenNano® Mice: A Heavy-Chain-Only Antibody Platform for the Generation of Nanobody Therapeutics
TCR Mimic Targeting Intracellular Tumor Antigens Using Fully Human TCR Mimic Antibodies Derived From HLA Transgenic RenMiceTM
HiTS Platform The RenMiceTM HiTS (Hyperimmune Target Specific) Platform Facilitates Identification of Novel Therapeutic Antibodies for Challenging Targets

Fully Human Monoclonal Antibody Assets

Antibody Target Poster
TNFR2 1C3, A Novel Non-Blocking Anti-Human TNFR2 Antibody, Promotes Effector T Cell Responses and Demonstrates Potent Anti-Tumor Activity
BCG008 BCG008, A Human Siglec-15 Blocking Antibody, Displays Potent Anti-Tumor Activity in Siglec-15-Humanized Mice
IL2RA D02, A Novel, Non-Blocking Antibody Targeting IL2RA, Exhibits Significant Anti-Tumor Activity in IL2RA-Humanized Mice
B7-H3 *Novel Preclinical Candidates Targeting B7-H3, 6B5 and 10F7, Are Suitable for Development Into Various Drug Modalities

RenLite®-derived Fully Human Bispecific ADC Assets

Bispecific ADC Poster
YH012 A First-In-Class Anti-HER2/TROP2 Bispecific Antibody-Drug Conjugate (YH012) Exhibits Potent Anti-Tumor Efficacy
BSA01 A Novel EGFR x MUC1 Bispecific Antibody-Drug Conjugate, BSA01, Targets MUC1 Transmembrane Cleavage Products and Improves Tumor Selectivity
BCG022 BCG022: A Novel Bispecific Antibody-Drug Conjugate Targeting HER3 and MET
BCG033 Discovery of BCG033, A Novel Anti-PTK7 x TROP2 Bispecific Antibody-Drug Conjugate with Promising Efficacy Against Triple-Negative Breast Cancer


The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world. (Source: AACR)


Back to top